Bafna Pharmaceuticals Limited
₹461.35▲ +9.00 (+1.99%)
BAFNAPH·NSE·Healthcare
Market Cap
1108.65 Cr
PE Ratio
98.37
Volume
20,630
Day High - Low
461.35 - 460.00
52W High-Low
461.35 - 94.77
₹461.35▲ +9.00 (+1.99%)
Market Cap1108.65 Cr
PE Ratio98.37
Volume20,630
Day High - Low461.35 - 460.00
52W High-Low461.35 - 94.77
Bafna Pharmaceuticals Limited (BAFNAPH): company summary
The company's annual revenue rose 3.2% year-over-year, but the latest quarter's revenue fell 23.2% compared to the same quarter a year earlier.
Bafna Pharmaceuticals Limited (BAFNAPH) is a micro-cap Healthcare company valued at ₹1,109 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Bafna Pharmaceuticals Limited last traded at ₹461.35, modestly up 1.99% on the day.
- Recent developments
- On 2026-06-30, the company reported a net profit of ₹0 crore for the latest quarter, down 97.6% from ₹3 crore in the same quarter a year earlier. On 2026-06-30, the company's revenue for the latest quarter was ₹27 crore, down 23.2% from ₹35 crore in the same quarter a year earlier. On 2026-06-30, the company did not pay a dividend despite reporting repeated profits.
- Financial performance
- The company's annual revenue rose 3.2% year-over-year, but the latest quarter's revenue fell 23.2% compared to the same quarter a year earlier. Annual net profit surged 177.5% year-over-year, but the latest quarter's net profit dropped 97.6% compared to the same quarter a year earlier. The net profit margin widened to 7.4% from 2.7% in the prior year.
- Valuation multiples
- The stock trades at 98.4 times earnings, a premium to the Healthcare median of 32.0, 7.31 times book value.
- Things to watch
- The latest quarter's net profit fell 97.6% compared to the same quarter a year earlier. The latest quarter's revenue dropped 23.2% compared to the same quarter a year earlier. The company is not paying out a dividend despite reporting repeated profits.
- Where it stands
- The company's annual net profit rose 177.5% year-over-year, but the latest quarter's net profit fell 97.6% compared to the same quarter a year earlier. The latest quarter's revenue dropped 23.2% compared to the same quarter a year earlier. The company's net profit margin widened to 7.4% from 2.7% in the prior year.
Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.1/10
Weak
Fair Value
Sign in to see
ROE
11.54%
Average
P/E
98.37x
Expensive
Debt / Equity
0.39
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹460.00
₹461.35
52W₹94.77
₹461.35
DocStoX take
Supported by risk (7.6) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 7.6, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence5.1
/10
Weak
Quality
Modest
ROE 11.5%
Valuation
Expensive
P/E 98.4×
Growth
Steady
Revenue +16.2% 5Y CAGR
Risk
Low risk
D/E 0.39
Momentum
Strong
100% of 52-week range
At a glance
Market Cap
₹1,109 Cr
52W High / Low
₹461 / ₹95
Dividend Yield
0.00%
Promoter Holding
75.00%
EPS (TTM)
₹4.69
Book Value
₹40.64
Key highlights
- Profitable in all of the last 5 years
- Revenue compounding 16% a year
- Valuation is weak (0.0/10)
- Expensive at 98× earnings
2 Positives2 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Bafna Pharmaceuticals Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Bafna Pharmaceuticals Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Bafna Pharmaceuticals Limited with peers
Bafna Pharmaceuticals Limited vs Sun Pharmaceutical Industries LimitedBafna Pharmaceuticals Limited vs Divi's Laboratories LimitedBafna Pharmaceuticals Limited vs Torrent Pharmaceuticals LimitedBafna Pharmaceuticals Limited vs Apollo Hospitals Enterprise LimitedBafna Pharmaceuticals Limited vs Zydus Lifesciences LimitedBafna Pharmaceuticals Limited vs Laurus Labs Limited
Related tools & concepts
Value Bafna Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing